Jade Biosciences, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Jade Biosciences, Inc. (JBIO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-03-06
- Jade Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-06 | |
| 2024-12-31 | -0.10% 10-K · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |